Efficacy, Safety and Pharmacokinetics of NNC0519-0130 Once Weekly s.c. Versussemaglutide 1.0 mg and Placebo in People With Chronic Kidney Disease, With or Without Type 2 Diabetes, and With Overweight or Obesity: a Proof-of-concept and Dose-finding Study
Efficacy, Safety and Pharmacokinetics of NNC0519-0130 Once Weekly s.c. Versussemaglutide 1.0 mg and Placebo in People With Chronic Kidney Disease, With or Without Type 2 Diabetes, and With Overweight or Obesity: a Proof-of-concept and Dose-finding Study
The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes, living with overweight or obesity. The participants will either get NNC0519-0130 (a new medicine), semaglutide (a medicine that doctors can already prescribe), or placebo (a "dummy" substance). Which treatment the participant will get is decided by chance. The study will last for up to 43 weeks.
Inclusion Criteria:
Female of non-childbearing potential, or male.
Age 18 years or above at the time of signing the informed consent.
Diagnosed with type 2 diabetes mellitus greater than or equal to (≥) 180 days before screening, or not diagnosed with type 2 diabetes mellitus.
BMI greater than or equal to (≥) 27.0 kilogram per square metre (kg/m^2) at screening.
Kidney impairment defined by serum creatinine and cystatin C-based Egfr greater than or equal to (≥) 15 and less than (<) 90 mL/min/1.73 m^2.
Albuminuria defined by Urine Albumin-to-Creatinine Ratio (UACR) greater than or equal (≥)100 and less than (<) 5000 milligram per gram (mg/g).
Treatment with maximum labelled or tolerated dose of an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), unless such treatment is contraindicated or not tolerated, in the opinion of the investigator. Treatment dose must be stable for at least 30 days prior to screening.
Exclusion Criteria:
clinicaltrials@novonordisk.com(+1) 866-867-7178
San Ramon, California 94583, United States
Winston-Salem, North Carolina 27103, United States
City of Buenos Aires, C1056ABI, Argentina
Mar del Plata, B7600FZN, Argentina
St Albans, Victoria 3021, Australia
Curitiba, Paraná 80045-110, Brazil
Porto Alegre, Rio Grande do Sul 90020-090, Brazil
Porto Alegre, Rio Grande do Sul 90430-001, Brazil
São Paulo, 04038-002, Brazil
Sofia, 1431, Bulgaria
Sofia, 1750, Bulgaria
L’Aquila, Abbruzzo 67100, Italy
Chieti, Abruzzo 66100, Italy
Koriyama-shi, Fukushima, Fukushima, Japan 963-8851, Japan
Aichi, 468-0009, Japan
Kita-ku, Tokyo, 114-0001, Japan
Sendai-shi, Miyagi, 983-0039, Japan
Sendai-shi, Miyagi, 983-0039, Japan
Siga, 523-0082, Japan
Siga, 523-0082, Japan
Lembah Pantai, Kuala Lumpur 59100, Malaysia
Włocławek, Kuyavian-Pomeranian Voivodeship 87-800, Poland
Rzeszów, Podkarpackie Voivodeship 35-301, Poland
Lodz, 90-153, Poland
Lodz, 92-213, Poland
Zabrze, 41-800, Poland
Goyang-si, Gyeonggi-do 10444, South Korea
Kayseri, Melikgazi 38039, Turkey (Türkiye)
Gaziantep, 27070, Turkey (Türkiye)
Istanbul, 34722, Turkey (Türkiye)